Improving Clinician-Patient Collaboration in the Management of Obesity: A Patient Seeking Treatment for Obesity
Weight ManagementImproving Clinician-Patient Collaboration in the Management of Obesity
0.5 AMA PRA Category 1 Credit(s) ™
October 01, 2019
The accreditation for this activity has expired.
Primary Audience:
Primary care physicians, endocrinologists, nurse practitioners, physician assistants, nurses
Relevant Terms:
Obesity, diabetes, and weight loss
Scott Kahan, MD, MPH
Director, National Center for Weight and Wellness
Medical Director, Strategies To Overcome and Prevent (STOP) Obesity Alliance
George Washington University Milken Institute School of Public Health
Chair, Clinical Committee, The Obesity Society
Washington, DC
Scott Kahan, MD, MPH is a preventive medicine and obesity medicine physician. He is Director of the National Center for Weight and Wellness and Medical Director for Strategies to Overcome and Prevent (S.T.O.P.) Obesity Alliance, a health policy think-tank and coalition of more than 100 organizations that drive innovative and practical strategies to address obesity.
Dr. Kahan received his undergraduate degree in bioengineering from Columbia University, his medical degree from the Medical College of Pennsylvania, and his residency training and Master’s of Public Health degree from Johns Hopkins University. He serves on the faculties of the Johns Hopkins Bloomberg School of Public Health, George Washington University School of Medicine and School of Public Health, and George Mason University College of Health and Human Services.
He has published 14 books in the fields of medicine, nutrition, and public health. He has advised the White House, US Congress, FDA, CMS, and numerous national, state, and local government and advocacy groups on issues pertaining to obesity, nutrition, and chronic disease prevention. He is a regular contributor to numerous media outlets, including NPR, USA Today, NY Times, CNN, Washington Post, Huffington Post, and others. He serves on the Board of Directors for the American Board of Obesity Medicine, Obesity Action Coalition, and Obesity Treatment Foundation. He is a scientific peer reviewer for more than 50 academic journals and research organizations. He has received numerous awards, including the 2017 Clinician of the Year from The Obesity Society.
Ken Fujioka, MD
Director, Nutrition and Metabolic Research Center
Scripps Clinic, Dept. of Endocrinology, Diabetes, and Metabolism
San Diego, CA
Dr. Fujioka is currently director of Nutrition and Metabolic Research and Obesity Telemedicine at Scripps Clinic in the Department of Diabetes and Endocrinology. He has completed over 150 clinical trials and authored over 100 peer reviewed papers. In 1997 he started the Center for Weight Management at Scripps Clinic; the Center has grown from one physician to over a dozen health care providers that cover all aspects of obesity treatment. The Center cares for over 1000 patients per month. The Weight Loss Center is completely insurance-based and a significant number of patients have managed care or accountable care. Dr. Fujioka is certified in Obesity Medicine by the American Board of Obesity Medicine.| 1. | Summarize physiological mechanisms involved in obesity and weight loss | 2. | Relate the impact of excess weight to morbidity and mortality, particularly with regard to type 2 diabetes, cardiovascular disease, and certain cancers |
| 3. | Review current guidelines for obesity management | 4. | Outline the approved anti-obesity medications and their mechanisms of action, efficacy, and safety |
| 5. | Describe the assessment of a patient with obesity and the development of a treatment plan |
| 1. | Summarize physiological mechanisms involved in obesity and weight loss |
| 2. | Relate the impact of excess weight to morbidity and mortality, particularly with regard to type 2 diabetes, cardiovascular disease, and certain cancers |
| 3. | Review current guidelines for obesity management |
| 4. | Outline the approved anti-obesity medications and their mechanisms of action, efficacy, and safety |
| 5. | Describe the assessment of a patient with obesity and the development of a treatment plan |
CONTINUING EDUCATION CREDIT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians. 
Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURES
All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of MCM Education and Purdue University College of Pharmacy have no relationships to disclose.
Dr. Kahan discloses the following:
Consultant: Novo Nordisk, Orexigen, Vivus, Amgen, Bausch, Biologix
Dr. Fujioka discloses the following:
Consultant: Amgen, Boehringer-Ingelheim, Eisai, Gelesis, Janssen Global Services, KVK-tech, Novo Nordisk, Sunovion
Grants/research support: Eisai
Speakers bureau: Novo Nordisk
Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.
DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
COMMERCIAL SUPPORT
This activity is supported by an educational grant from Novo Nordisk Inc.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
